Similarly, we reported a striking example of how tumor heterogeneity between individual metastases at the time of acquired resistance can lead to mixed response and treatment failure in a CRC patient following acquired resistance to the anti-EGFR antibody cetuximab [17]. Here, EGFR is linked to colorectal carcinoma.